Novoheart Announces Successful Completion of Second Commercial Contract with Global Pharmaceutical Company

Novoheart is pleased to announce the successful completion of a second commercial contract with a major global pharma partner, where Novoheart successfully designed and generated engineered human heart cells, tissues and chambers that carried a hereditary neurological disorder with cardiac dysfunction being the most frequent cause of death, in over two thirds of the afflicted individuals. The various disease-specific heart constructs are then used as the only human heart tissue models available for testing novel therapeutic candidates that target the disease. The second contract was initiated after a successful initial collaboration that validated the drug screening capabilities of Novoheart's proprietary MyHeart™ Platform. 

Under the agreement, Novoheart has retained ownership of intellectual property generated from the project. A joint scientific report is currently being finalized by both parties, and will be submitted for publication in a peer-reviewed scientific journal. Further details will be announced separately.

For the detailed press release, please click here.

Subscribe To Our Newsletter

Fill out the following to subscribe and start receiving updates from us!